林子又

Publications

2023

Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.

Lin Z, Li J, Zhang J, Feng W, Lu J, Ma X, Ding W, Ouyang S, Lu J, Yue P, Wan G, Liu P*, Zhang X*.

Cancer Res. 2023 Jul 5;83(13):2187-2207.·2023·DOI

N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis.

Lin Z, Wan AH, Sun L, Liang H, Niu Y, Deng Y, Yan S, Wang QP, Bu X, Zhang X, Hu K*, Wan G*, He W*.

Mol Ther. 2023 Feb 1;31(2):517-534.·2023·DOI

2021

Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.

Niu Y, Lin Z, Wan A, Sun L, Yan S, Liang H, Zhan S, Chen D, Bu X, Liu P, Chen C, He W, Lu X, Wan G*.

Hepatology. 2021 Sep;74(3):1461-1479.·2021·DOI

RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer.

Sun L#, Wan A#, Zhou Z, Chen D, Liang H, Liu C, Yan S, Niu Y, Lin Z, Zhan S, Wang S, Bu X, He W, Lu X*, Xu A*, Wan G*.

Gut. 2021 Sep;70(9):1698-1712.·2021·DOI

2020

RNA m6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy.

Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, Zhang X, Bu X, He W*, Wan G*.

EMBO J. 2020 Jun 17;39(12):e103181.·2020·DOI

2019

RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.

Niu Y, Lin Z, Wan A, Chen H, Liang H, Sun L, Wang Y, Li X, Xiong XF, Wei B*, Wu X*, Wan G*.

Mol Cancer. 2019 Mar 28;18(1):46.·2019·DOI

2018

N6-Methyladenosine modification: a novel pharmacological target for anti-cancer drug development.🗍

Niu Y, Wan A, Lin Z, Lu X, Wan G*.

Acta Pharm Sin B. 2018 Oct;8(6):833-843.·2018·DOI